FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2052204551> ?p ?o ?g. }

• W2052204551 endingPage "2049" @default.
• W2052204551 startingPage "2041" @default.
• W2052204551 abstract "Assess the 12-month efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg ranibizumab in patients with macular edema after central retinal vein occlusion (CRVO).Prospective, randomized, sham injection-controlled, double-masked, multicenter clinical trial.We included 392 patients with macular edema after CRVO.Eligible patients were randomized 1:1:1 to receive 6 monthly intraocular injections of 0.3 mg or 0.5 mg of ranibizumab or sham injections. After 6 months, all patients with BCVA ≤20/40 or central subfield thickness ≥250 μm could receive ranibizumab.Mean change from baseline best-corrected visual acuity (BCVA) letter score at month 12, additional parameters of visual function, central foveal thickness (CFT), and other anatomic changes were assessed.Mean (95% confidence interval) change from baseline BCVA letter score at month 12 was 13.9 (11.2-16.5) and 13.9 (11.5-16.4) in the 0.3 mg and 0.5 mg groups, respectively, and 7.3 (4.5-10.0) in the sham/0.5 mg group (P<0.001 for each ranibizumab group vs. sham/0.5 mg). The percentage of patients who gained ≥15 letters from baseline BCVA at month 12 was 47.0% and 50.8% in the 0.3 mg and 0.5 mg groups, respectively, and 33.1% in the sham/0.5 mg group. On average, there was a marked reduction in CFT after the first as-needed injection of 0.5 mg ranibizumab in the sham/0.5 mg group to the level of the ranibizumab groups, which was sustained through month 12. No new ocular or nonocular safety events were identified.On average, treatment with ranibizumab as needed during months 6 through 11 maintained the visual and anatomic benefits achieved by 6 monthly ranibizumab injections in patients with macular edema after CRVO, with low rates of ocular and nonocular safety events. After sham injections for 6 months, treatment with ranibizumab as needed for 6 months resulted in rapid reduction in CFT in the sham/0.5 mg group to a level similar to that in the 2 ranibizumab treatment groups and an improvement in BCVA, but not to the same level as that in the 2 ranibizumab groups. Intraocular injections of ranibizumab provide an effective treatment for macular edema after CRVO.Proprietary or commercial disclosure may be found after the references." @default.
• W2052204551 created "2016-06-24" @default.
• W2052204551 creator A5022551584 @default.
• W2052204551 creator A5022681939 @default.
• W2052204551 creator A5027224484 @default.
• W2052204551 creator A5030449236 @default.
• W2052204551 creator A5063622809 @default.
• W2052204551 creator A5065814663 @default.
• W2052204551 creator A5085600986 @default.
• W2052204551 creator A5085965174 @default.
• W2052204551 creator A5089896434 @default.
• W2052204551 date "2011-10-01" @default.
• W2052204551 modified "2023-10-14" @default.
• W2052204551 title "Sustained Benefits from Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Twelve-Month Outcomes of a Phase III Study" @default.
• W2052204551 cites W1977995451 @default.
• W2052204551 cites W2031329755 @default.
• W2052204551 cites W2054551550 @default.
• W2052204551 cites W2068100937 @default.
• W2052204551 cites W2128701654 @default.
• W2052204551 cites W2154763327 @default.
• W2052204551 cites W2161524242 @default.
• W2052204551 cites W2767447900 @default.
• W2052204551 cites W4239471829 @default.
• W2052204551 doi "https://doi.org/10.1016/j.ophtha.2011.02.038" @default.
• W2052204551 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21715011" @default.
• W2052204551 hasPublicationYear "2011" @default.
• W2052204551 type Work @default.
• W2052204551 sameAs 2052204551 @default.
• W2052204551 citedByCount "550" @default.
• W2052204551 countsByYear W20522045512012 @default.
• W2052204551 countsByYear W20522045512013 @default.
• W2052204551 countsByYear W20522045512014 @default.
• W2052204551 countsByYear W20522045512015 @default.
• W2052204551 countsByYear W20522045512016 @default.
• W2052204551 countsByYear W20522045512017 @default.
• W2052204551 countsByYear W20522045512018 @default.
• W2052204551 countsByYear W20522045512019 @default.
• W2052204551 countsByYear W20522045512020 @default.
• W2052204551 countsByYear W20522045512021 @default.
• W2052204551 countsByYear W20522045512022 @default.
• W2052204551 countsByYear W20522045512023 @default.
• W2052204551 crossrefType "journal-article" @default.
• W2052204551 hasAuthorship W2052204551A5022551584 @default.
• W2052204551 hasAuthorship W2052204551A5022681939 @default.
• W2052204551 hasAuthorship W2052204551A5027224484 @default.
• W2052204551 hasAuthorship W2052204551A5030449236 @default.
• W2052204551 hasAuthorship W2052204551A5063622809 @default.
• W2052204551 hasAuthorship W2052204551A5065814663 @default.
• W2052204551 hasAuthorship W2052204551A5085600986 @default.
• W2052204551 hasAuthorship W2052204551A5085965174 @default.
• W2052204551 hasAuthorship W2052204551A5089896434 @default.
• W2052204551 hasConcept C118487528 @default.
• W2052204551 hasConcept C126322002 @default.
• W2052204551 hasConcept C141071460 @default.
• W2052204551 hasConcept C168563851 @default.
• W2052204551 hasConcept C2776694085 @default.
• W2052204551 hasConcept C2777802072 @default.
• W2052204551 hasConcept C2778257484 @default.
• W2052204551 hasConcept C2778844676 @default.
• W2052204551 hasConcept C2780347916 @default.
• W2052204551 hasConcept C2780827179 @default.
• W2052204551 hasConcept C2781100027 @default.
• W2052204551 hasConcept C44249647 @default.
• W2052204551 hasConcept C71924100 @default.
• W2052204551 hasConceptScore W2052204551C118487528 @default.
• W2052204551 hasConceptScore W2052204551C126322002 @default.
• W2052204551 hasConceptScore W2052204551C141071460 @default.
• W2052204551 hasConceptScore W2052204551C168563851 @default.
• W2052204551 hasConceptScore W2052204551C2776694085 @default.
• W2052204551 hasConceptScore W2052204551C2777802072 @default.
• W2052204551 hasConceptScore W2052204551C2778257484 @default.
• W2052204551 hasConceptScore W2052204551C2778844676 @default.
• W2052204551 hasConceptScore W2052204551C2780347916 @default.
• W2052204551 hasConceptScore W2052204551C2780827179 @default.
• W2052204551 hasConceptScore W2052204551C2781100027 @default.
• W2052204551 hasConceptScore W2052204551C44249647 @default.
• W2052204551 hasConceptScore W2052204551C71924100 @default.
• W2052204551 hasIssue "10" @default.
• W2052204551 hasLocation W20522045511 @default.
• W2052204551 hasLocation W20522045512 @default.
• W2052204551 hasOpenAccess W2052204551 @default.
• W2052204551 hasPrimaryLocation W20522045511 @default.
• W2052204551 hasRelatedWork W1997095687 @default.
• W2052204551 hasRelatedWork W2093993639 @default.
• W2052204551 hasRelatedWork W2414485424 @default.
• W2052204551 hasRelatedWork W2521155275 @default.
• W2052204551 hasRelatedWork W2588621177 @default.
• W2052204551 hasRelatedWork W2802976037 @default.
• W2052204551 hasRelatedWork W2895848666 @default.
• W2052204551 hasRelatedWork W3147589859 @default.
• W2052204551 hasRelatedWork W4205243730 @default.
• W2052204551 hasRelatedWork W3115407169 @default.
• W2052204551 hasVolume "118" @default.
• W2052204551 isParatext "false" @default.
• W2052204551 isRetracted "false" @default.
• W2052204551 magId "2052204551" @default.
• W2052204551 workType "article" @default.